China Pharma Files Prospectus Supplement With The U.S. SEC Under Which The Company May Offer And Sell From Time To Time Shares Of Common Stock, With An Aggregate Offering Price Of Up To $600,000
China Pharma Files Prospectus Supplement With The U.S. SEC Under Which The Company May Offer And Sell From Time To Time Shares Of Common Stock, With An Aggregate Offering Price Of Up To $600,000
惠普森醫藥向美國證券交易委員會提交了補充招股說明書，根據該說明書，公司可能會不時發行和賣出普通股，累計發行價格可達60萬美元。
China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") under which the Company may offer and sell from time to time shares of common stock, par value $0.001 per share (the "Common Stock"), with an aggregate offering price of up to $600,000 (the "Financing").
惠普森醫藥控股公司（紐交所：CPHI）（"惠普森醫藥"或"公司"），是一家專業藥品公司，今日宣佈已向美國證券交易委員會（"SEC"）提交了一份招股說明書補充文件，根據該文件，公司可能不時提供和出售普通股，面值爲每股0.001美元（"普通股"），總髮行價格高達600,000美元（"融資"）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。